



ASX ANNOUNCEMENT

NEUROSCIENTIFIC STRATEGIC PLACEMENT TO ALPHASWISS PARTNERS

Perth, Australia; 11 November 2020. NeuroScientific Biopharmaceuticals Ltd ASX: NSB ("NeuroScientific" or "the Company"), is pleased to announce it has received commitments from Geneva, Switzerland-based AlphaSwiss Partners SA for the placement of 8,571,429 fully paid ordinary shares in the Company at an issue price of \$0.28 per share to raise \$2.4 million before costs (**Placement**). The issue price represents a 6.8% discount to the 15- trading day VWAP.

Chief Executive Officer and Managing Director, Matt Liddelow commented, "it is pleasing to attract investment from an international investment group of the calibre of AlphaSwiss and their investment represents a major endorsement of NeuroScientific's research and development program. We also look forward to benefiting from the deep network of industry contacts that comes with AlphaSwiss."

About AlphaSwiss

AlphaSwiss is a well-respected family office based out of Geneva, Switzerland with circa \$1.8 Billion USD under management. Their investment philosophy based on innovation and independent thinking has provided their clients with exceptional early investment opportunities, with a number of long-term strategic investments in global companies such as Dropbox, DocuSign, Lyft, and others.

Use of Funds

The current placement provides the Company with the necessary funds to finish its preclinical safety and toxicology programs in ophthalmology and neurology as well as accelerate the start of a Phase 1 study in patients suffering from Glaucoma. Additionally, funds from the placement will allow the Company to start a Phase 1 study in healthy volunteers to support its neurodegenerative indications.

Brian Leedman, Chairman of NeuroScientific Biopharmaceuticals commented, "in the past few months NeuroScientific has presented initial data from animal studies with induced intraocular pressure to pharmaceutical companies and have received strong interest. We are looking forward to bringing this disease modifying therapy to patients in the near future".

Westar Capital Ltd acted as lead manager to the raise and will receive a 6% capital raising fee as well as 1,600,000 unlisted options with an exercise price of \$0.45 each and an expiry date 2-years from issue.

About NeuroScientific Biopharmaceuticals Limited

NeuroScientific Biopharmaceuticals (ASX:NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB. For more information, please visit www.neuroscientific.com

END

Announcement authorised by the Board of Directors of NeuroScientific Biopharmaceuticals

Contacts

Matthew Liddelow
CEO and Managing Director
ml@neuroscientific.com
+61 8 6382 1805

Brian Leedman
Nonexecutive Chairman
bl@neuroscientific.com
+61 412 281 780